Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects

Next Previous
X
Search
Trial Profile

Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 3532795 (Primary) ; Atazanavir; Emtricitabine; Ritonavir; Tenofovir
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; ViiV Healthcare

    • Most Recent Events

    • 23 Mar 2017 Results published in the Clinical Infectious Diseases
    • 25 Feb 2016 Results of (pharmacokinetic & exposure-response analysis) part A of this trial presented at the 23rd Conference on Retroviruses and Opportunistic Infections.
    • 23 Oct 2015 Results from this trial were presented at the European AIDS Clinical Society's 15th European AIDS Conference (EACS), according to a Bristol-Myers Squibb media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top